Cheng Qiu, Fan Dandan, Chen Pengyu, Yuan Huaihong
Department of Nephrology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, No. 363, Section 3, Furong Avenue, Yongning Street, Wenjiang District, Chengdu, 610041, Sichuan, China.
Int Urol Nephrol. 2025 Feb 3. doi: 10.1007/s11255-025-04400-w.
Hemodialysis (HD) patients commonly experience enhanced oxidative stress and inflammation, potentially increasing the risk of malnutrition. Selenium levels are typically lower in HD individuals. Selenium deficiency has been identified as a risk factor for oxidative stress and inflammatory responses. Therefore, we intended to perform a meta-analysis to assess the impact of selenium supplementation on HD patients.
PubMed, Embase, Cochrane Library, and Web of Science were searched for randomized controlled trials (RCTs) on the effect of selenium supplementation on HD patients until September 31, 2024. The data analysis was conducted using Stata15.0 software.
Seven RCTs, with 2080 participants, were finally included, with 1029 in the selenium group and 1051 in the control group. The meta-analysis unraveled no statistically significant impact of selenium supplementation on body mass index (SMD = 0.15, 95% CI (- 0.20, 0.49), triglyceride [(SMD = - 0.02, 95% CI (- 0.44, 0.41)], total cholesterol [(SMD = - 0.18, 95%CI (- 0.41, 0.05)], low-density lipoprotein [(SMD = - 0.37, 95% CI (- 1.04, 0.31)], high-density lipoprotein cholesterol [(SMD = 0.15, 95% CI (- 0.54, 0.84)], C-reactive protein [(SMD = - 0.10, 95% CI (- 0.46, 0.27)], ferritin [(SMD = - 0.02, 95% CI (- 0.29, 0.26)], Hx-C reactive protein [(SMD = 0.00, 95% CI (- 1.02, 1.03)], and hemoglobin [(SMD = 0.01, 95% CI (- 0.57,0.59)]. Only selenium levels were significantly increased after selenium supplementation [SMD = 2.83, 95% CI (2.43, 3.24)].
Selenium supplementation can increase selenium levels in HD patients, without notable impacts on weight, triglycerides, and total cholesterol.
血液透析（HD）患者通常会经历氧化应激和炎症增强，这可能会增加营养不良的风险。HD患者的硒水平通常较低。硒缺乏已被确定为氧化应激和炎症反应的一个风险因素。因此，我们旨在进行一项荟萃分析，以评估补充硒对HD患者的影响。
检索了PubMed、Embase、Cochrane图书馆和Web of Science，以查找截至2024年9月31日关于补充硒对HD患者影响的随机对照试验（RCT）。使用Stata15.0软件进行数据分析。
最终纳入了7项RCT，共2080名参与者，其中硒组1029名，对照组1051名。荟萃分析表明，补充硒对体重指数（标准化均值差[SMD]=0.15，95%置信区间CI）、甘油三酯（[SMD=-0.02，95%CI(-0.44,0.41)]）、总胆固醇（[SMD=-0.18，95%CI(-0.41,0.05)]）、低密度脂蛋白（[SMD=-0.37，95%CI(-1.04,0.31)]）、高密度脂蛋白胆固醇（[SMD=0.15，95%CI(-0.54,0.84)]）、C反应蛋白（[SMD=-0.10，95%CI(-0.46,0.27)]）、铁蛋白（[SMD=-0.02，95%CI(-0.29,0.26)]）、高敏C反应蛋白（[SMD=0.00，95%CI(-1.02,1.03)]）和血红蛋白（[SMD=0.01，95%CI(-0.57,0.59)]）均无统计学上的显著影响。只有补充硒后硒水平显著升高[SMD=2.83，95%CI(2.43,3.24)]。
补充硒可提高HD患者的硒水平，但对体重、甘油三酯和总胆固醇无显著影响。
